

SWOG Cancer Research Network-led oral and poster presentations at ASCO 2024

All times are Central Time

Information on abstracts and presentations led by other NCTN groups with contributions from SWOG investigators is available at <https://www.swog.org/media/19872>.

Study # & Disease Committee(s)	Friday, May 31, 2024	What, Where, & When
S1007 RxPONDER Breast Cancer	Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial First Author: Yara Abdou, MD	Rapid Oral Abstract Session Session: Breast Cancer—Local/Regional/Adjuvant Abstract #: 515 May 31, 3:39 – 3:45 pm, E451 Session runs 2:45 – 4:15 pm

SWOG Cancer Research Network-led oral and poster presentations at ASCO 2024

Study # & Disease Committee(s)	Saturday, June 1, 2024	What, Where, & When
S1800D Lung-MAP Lung Cancer	Lung-MAP S1800D: A phase II/III study of N-803 (ALT-803) plus pembrolizumab versus standard of care in participants with stage IV or recurrent non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy First Author: John M. Wrangle, MD, MPH	Poster Session Session: Developmental Therapeutics-- Immunotherapy Abstract #: 2619 Poster Bd #: 98 June 1, 9 am – 12 pm, Hall A
S1609 DART Early Therapeutics & Rare Cancers	Correlations between first cycle toxicity and overall survival in patients with rare cancers treated with immune checkpoint inhibitors (NCI/SWOG S1609) First Author: Megan Othus, PhD	Poster Session Session: Developmental Therapeutics-- Immunotherapy Abstract #: 2655 Poster Bd #: 134 June 1, 9 am – 12 pm, Hall A
S2107 Gastrointestinal Cancer	SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer First Author: Van K. Morris, MD	Poster Session Session: Gastrointestinal Cancer – Colorectal and Anal Abstract #: TPS3640 Poster Bd #: 298a June 1, 1:30 – 4:30 pm, Hall A
S2012 Gastrointestinal Cancer	SWOG S2012: Randomized phase II/III trial of first line platinum (P)/etoposide (E) with or without atezolizumab (NSC #783608) in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC) First Author: David Bing Zhen, MD	Poster Session Session: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary Abstract #: TPS4201 Poster Bd #: 170b June 1, 1:30 – 4:30 pm, Hall A
S1404 Melanoma	Association between circulating tumor DNA (ctDNA) and recurrence-free survival (RFS) in patients (pts) with resected stage III melanoma: An exploratory analysis of SWOG S1404 First Author: Michael Brian LaPelusa, MD	Poster Session Session: Melanoma / Skin Cancers Abstract #: 9564 Poster Bd #: 348 June 1, 1:30 – 4:30 pm, Hall A

SWOG Cancer Research Network-led oral and poster presentations at ASCO 2024

Study # & Disease Committee(s)	Sunday, June 2, 2024	What, Where, & When
S1714 Symptom Management & Quality of Life	Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Patients with Early-Stage Cancer Receiving Taxane Therapy: SWOG S1714 (NCT#03939481) First Author: Meghna S. Trivedi, MD, MS	Oral Abstract Session Session: Symptom Science and Palliative Care Abstract #: 12005 June 2, 9:24 – 9:36 am Session 8 – 11 am, S100A
S1216 Genitourinary Cancer	Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study First Author: Umang Swami, MD	Poster Session Session: Genitourinary Cancer—Prostate, Testicular, and Penile Abstract #: 5081 Poster Bd #: 487 June 2, 9 am – 12 pm, Hall A
S1937 Genitourinary Cancer	A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design First Author: Sarmad Sadeghi, MD, PhD	Poster Session Session: Genitourinary Cancer—Kidney and Bladder Abstract #: TPS4617 Poster Bd #: 307a June 2, 9 am – 12 pm, Hall A
S1609 DART Early Therapeutics & Rare Cancers	Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609) First Author: Young Kwang Chae, MD, MPH, MBA	Rapid Oral Abstract Session Session: Developmental Therapeutics -- Immunotherapy Abstract #: 2514 June 2, 11:36 – 11:42 am, S406 Session runs 11:30 am – 1 pm, S406

SWOG Cancer Research Network-led oral and poster presentations at ASCO 2024

Study # & Disease Committee(s)	Monday, June 3, 2024	What, Where, & When
S1600 Symptom Management and Survivorship	Effects of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes: Primary Results from the Randomized Phase III Double-Blind Clinical Trial (S1600) First Author: Jill Hamilton-Reeves, PhD	Oral Abstract Session Session: Genitourinary Cancer – Kidney & Bladder Abstract #: 4501 June 3, 8:00 – 8:12 am Session runs 8 – 11 am, Hall B1
S2213 Myeloma	A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis First Author: Patrick Hagen, MD, MPH	Poster Session Session: Hematologic Malignancies—Plasma Cell Dyscrasia Abstract #: TPS7575 Poster Bd #: 211b June 3, 9 am – 12 pm, Hall A
S1203 Leukemia	Treatment discontinuation due to toxicity for patients with acute myeloid leukemia (AML) treated on SWOG S1203. First Author: Suravi Raychaudhuri, MD	Poster Session Session: Hematologic Malignancies--Leukemia, Myelodysplastic Syndromes, and Allograft Abstract #: 6529 Poster Bd #: 88 June 3, 9 am – 12 pm, Hall A
Multiple Trials Cancer Care Delivery	Risk prediction model for acute care use among patients with advanced cancer on clinical trials First Author: Dawn L. Hershman, MD, MS	Poster Session Session: Quality Care / Health Services Research Abstract #: 11074 Poster Bd #: 269 June 3, 9 am – 12 pm, Hall A
Multiple Trials Cancer Care Delivery	Impact of the COVID-19 pandemic mitigation strategies on cancer treatment trials: A meta-analysis of industry and NCI studies First Author: Joseph Unger, PhD	Poster Session Session: Quality Care / Health Services Research Abstract #: 11021 Poster Bd #: 216 June 3, 9 am – 12 pm, Hall A
S2302 Pragmatica-Lung Lung Cancer	Multi-stakeholder, intentional outreach for improving representative recruitment in Pragmatica-Lung (SWOG S2302) First Author: Daniel R. Carrizosa, MD, MS	Poster Session Session: Quality Care / Health Services Research Abstract #: 11019 Poster Bd #: 214 June 3, 9 am – 12 pm, Hall A
Multiple Trials Symptom Management and Survivorship	Patient-reported fatigue and risk of treatment-related adverse events (AEs) in patients receiving systemic therapy in cancer clinical trials First Author: Joseph Unger, PhD	Rapid Oral Abstract Session Session: Quality Care / Health Services Research Abstract #: 11015 June 3, 2:15 – 2:21 pm Session runs 1:15 – 2:45 pm, S102
S0424 & others Lung	Prospective “common arm” comparison of US SWOG S0424 and Japanese JME studies in early-stage non-small cell lung cancer (NSCLC): Survival	Poster Session Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Abstract #: 8036

SWOG Cancer Research Network-led oral and poster presentations at ASCO 2024

	<p>differences in the context of race, gender and smoking First Author: Philip C. Mack, PhD</p>	<p>Poster Bd #: 298 June 3, 1:30 – 4:30 pm, Hall A</p>
<p>S1701 Lung Cancer</p>	<p>S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma First Author: Anne S. Tsao, MD</p>	<p>Poster Session Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Abstract #: 8110 Poster Bd #: 372 June 3, 1:30 – 4:30 pm, Hall A</p>
<p>S2302 Pragmatica-Lung Lung Cancer</p>	<p>SWOG S2302, PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer First Author: Karen L. Reckamp, MD</p>	<p>Poster Session Session: Lung Cancer—Non-Small Cell Metastatic Abstract #: TPS8657 Poster Bd #: 516b June 3, 1:30 – 4:30 pm, Hall A</p>
<p>S1007 RxPONDER Breast Cancer</p>	<p>Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER) First Author: Kevin Kalinsky, MD, MS</p>	<p>Oral Abstract Session Session: Breast Cancer – Local/Regional/Adjuvant Abstract #: 505 Poster Bd #: June 3, 4:24 – 4:36 pm Session 3 – 6 pm, Hall B1</p>
<p>S8814 & S1007 RxPONDER Breast Cancer</p>	<p>Development and validation of RSclin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-) node-positive breast cancer First Author: Lajos Pusztai, MD, DPhil</p>	<p>Oral Abstract Session Session: Breast Cancer – Local/Regional/Adjuvant Abstract #: 508 Poster Bd #: June 3, 5:24 – 5:36 pm Session 3 – 6 pm, Hall B1</p>